


Note: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the Japanese original, the latter shall prevail.

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending February 29, 2024 (under Japanese GAAP)



October 10, 2023



Company name: **LIFE CORPORATION**
 Listing: Tokyo Stock Exchange
 Securities code: 8194
 URL: <http://www.lifecorp.jp/>
 Representative: Takaharu Iwasaki, Representative Director and President
 Inquiries: Kazuo Kaneko, Executive Officer, Deputy Division COO, Corporate Finance and Accounting Division, and General Manager, Investor Relations Department
 TEL: +81-3-5807-5111 (from overseas)

Scheduled date to file Quarterly Securities Report: October 13, 2023
 Scheduled date to commence dividend payments: November 1, 2023
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results meeting: Yes (for institutional investors and analysts)

(Amounts less than one million yen are rounded down.)

1. Consolidated financial results for the first six months of the fiscal year ending February 29, 2024 (from March 1, 2023 to August 31, 2023)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Operating revenue		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended August 31, 2023	400,148	6.0	12,410	39.2	12,851	37.7	8,534	33.1
August 31, 2022	377,563	–	8,914	(41.6)	9,331	(40.2)	6,412	(40.5)

Note: Comprehensive income
 Six months ended August 31, 2023: ¥8,580 million [32.7%]
 Six months ended August 31, 2022: ¥6,468 million [(39.2)%]

Reference: Operating revenue is the total of net sales and receipts from operating revenue.

Net sales
 Six months ended August 31, 2023: ¥385,663 million [5.9%]
 Six months ended August 31, 2022: ¥364,251 million [–%]
 Receipts from operating revenue
 Six months ended August 31, 2023: ¥14,484 million [8.8%]
 Six months ended August 31, 2022: ¥13,311 million [–%]

	Earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
August 31, 2023	181.87	–
August 31, 2022	136.83	–

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29), etc., from the beginning of the first quarter of the fiscal year ended February 28, 2023. Figures for the six months ended August 31, 2022 represent the amounts after applying the said accounting standard, etc., and do not include year-on-year changes for operating revenue.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
August 31, 2023	279,673	128,945	46.1	2,747.53
February 28, 2023	280,810	122,002	43.4	2,599.79

Reference: Equity

As of August 31, 2023: ¥128,945 million

As of February 28, 2023: ¥122,002 million

2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended February 28, 2023	–	35.00	–	35.00	70.00
Fiscal year ending February 29, 2024	–	40.00			
Fiscal year ending February 29, 2024 (Forecast)			–	40.00	80.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending February 29, 2024 (from March 1, 2023 to February 29, 2024)

(Percentages indicate year-on-year changes.)

	Operating revenue		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending February 29, 2024	801,000	4.6	19,800	3.4	20,500	2.4	13,500	1.3	288.02

Note: Revisions to the consolidated earnings forecasts most recently announced: None

* Notes

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None
- (2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
 - i. Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - ii. Changes in accounting policies due to other reasons: None
 - iii. Changes in accounting estimates: Yes
 - iv. Restatement: None
- (4) Number of issued shares (ordinary shares)
 - i. Total number of issued shares at the end of the period (including treasury shares)

As of August 31, 2023	49,450,800 shares
As of February 28, 2023	49,450,800 shares
 - ii. Number of treasury shares at the end of the period

As of August 31, 2023	2,519,389 shares
As of February 28, 2023	2,522,786 shares
 - iii. Average number of shares during the period (cumulative from the beginning of the fiscal year)

Six months ended August 31, 2023	46,929,037 shares
Six months ended August 31, 2022	46,869,043 shares

Note: The number of treasury shares at the end of the period includes the Company's shares (80,500 shares as of August 31, 2023, and 84,300 shares as of February 28, 2023) held by Custody Bank of Japan, Ltd. (Trust Account) as the trust assets for the "Trust for Delivering Shares to Directors."

In addition, the Company's shares held by Custody Bank of Japan, Ltd. (Trust Account) are included in the treasury shares that are excluded from the calculation of the average number of shares during the period. (83,136 shares for the six months ended August 31, 2023, and 88,520 shares for the six months ended August 31, 2022)

* Quarterly financial results reports are not required to be subjected to quarterly financial reviews conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Actual business and other results may differ substantially due to various factors.